Literature DB >> 3019276

Effect of suloctidil on rat liver.

D Thines-Sempoux, C Bovy-Kesler, E Debruyne, J Roba.   

Abstract

The effect of suloctidil (120 mg/kg body weight PO for 3 weeks) on rat liver was investigated using biochemical and morphological methods: enzymatic activities characteristic of the main cellular compartments were used as biochemical markers of hepatocyte function and morphometry was applied to investigate morphological changes. No sign of hepatotoxicity was evidenced after suloctidil treatment (liver weight; cytochrome c oxidase; glucose 6-phosphatase; NADPH-cytochrome c reductase; D-amino acid oxidase; urate oxidase; fatty acid oxidation; peroxisomal number, volume and size distribution). Suloctidil increased catalase activity by 22% without morphologically detectable changes in the peroxisomes. After suloctidil treatment, slightly increased mitochondrial volume fraction and slightly decreased mitochondrial number were noted without significant changes in cytochrome c oxidase. Clofibrate, at the same dose, increased NADPH-cytochrome c reductase, catalase, acylCoA oxidase, mitochondrial and peroxisomal number and volume fraction, and decreased urate oxidase activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019276     DOI: 10.1007/bf00286734

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  36 in total

1.  Potential antilipolytic activity of suloctidil.

Authors:  R Roncucci; J Roba; G Lambelin; M Ferenczi; V Blaton; D Vandamme; H Peeters
Journal:  Naturwissenschaften       Date:  1975-03

2.  [Evaluation of therapeutic effect of suloctidil in aged patients with cerebrovascular insufficiency. Double-blind study in comparison with placebo].

Authors:  J Bargheon
Journal:  Acta Clin Belg       Date:  1977       Impact factor: 1.264

3.  Studies on the hepatomegaly caused by the hypolipidemic drugs nafenopin and clofibrate.

Authors:  R B Beckett; R Weiss; R E Stitzel; R J Cenedella
Journal:  Toxicol Appl Pharmacol       Date:  1972-09       Impact factor: 4.219

4.  [Suloctidil hepatitis: bringing into focus].

Authors:  M H Capron; F Cabrières; J Lauga
Journal:  Presse Med       Date:  1984-10-06       Impact factor: 1.228

5.  Elevated liver enzymes in serum during suloctidil treatment.

Authors:  J A Schouten; R F Westerman
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  A secondary prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke.

Authors:  M Gent; J A Blakely; V Hachinski; R S Roberts; H J Barnett; N H Bayer; S G Carruthers; S M Collins; M G Gawel; M Giroux-Klimek
Journal:  Stroke       Date:  1985 May-Jun       Impact factor: 7.914

7.  Three hypolipidemic drugs increase hepatic palmitoyl-coenzyme A oxidation in the rat.

Authors:  P B Lazarow
Journal:  Science       Date:  1977-08-05       Impact factor: 47.728

8.  Controlled trial of suloctidil in intermittent claudication.

Authors:  R Verhaeghe; A Van Hoof; G Beyens
Journal:  J Cardiovasc Pharmacol       Date:  1981 Mar-Apr       Impact factor: 3.105

9.  A double-blind trial of suloctidil v. placebo in intermittent claudication.

Authors:  N A Jones; H De Haas; J Zahavi; V V Kakkar
Journal:  Br J Surg       Date:  1982-01       Impact factor: 6.939

10.  Structure, composition, physical properties, and turnover of proliferated peroxisomes. A study of the trophic effects of Su-13437 on rat liver.

Authors:  F Leighton; L Coloma; C Koenig
Journal:  J Cell Biol       Date:  1975-11       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.